ABSTRACT
Introduction Although the pathophysiology of obesity is widely recognized, its psychological and social aspects have received more attention in treatment and prevention. Social media technological advancements offer a quicker, more accessible, and broader platform for the dissemination of information. Hence, social media may significantly impact eating habits and body image development in children and adolescents, potentially turning into a risk factor for obesity if the behaviors being pushed are not consistent with a healthy lifestyle. Aim This study aims to evaluate the quality and reliability of content being circulated on Instagram related to the disease "obesity." Methods A cross-sectional observational study was conducted virtually over a period of ten days. Six hashtags related to the disease "obesity" were screened. Posts in the languages "English" or "Hindi" containing information about the disease "obesity" were included in the study. A questionnaire was made to assess these posts based on various pre-determined categories: type of post, type of information circulated, quality, reliability, and correctness. Results After applying the inclusion criteria, 420 posts were included in our study. 84% of the relevant posts were images/posts, and 15% were videos. Only 17% were posted by doctors, while the health and wellness industry posted around 54.52%. Survivors/persons suffering from the disease contributed to 13.81%, while that from dietitians was 6.43%, and that from new agencies was only 1.19%. The number of correct posts by doctors, nurses, and hospitals was 54.93%, and others were 37.7%. The posts by doctors, nurses, and hospitals were more reliable compared to others (statistically significant p<0.05). Conclusion This study highlights the need for continued monitoring and evaluation of the social media platform Instagram for the spread of healthcare information.
ABSTRACT
Acute intermittent porphyria (AIP) is an autosomal dominant disorder of heme biosynthesis in the liver that is caused by the accumulation of toxic heme metabolites aminolevulinic acid (ALA) and porphobilinogen (PBG) due to a deficiency in the enzyme hydroxymethylbilane synthase (HMBS). The prevalence of AIP is found to commonly affect females of reproductive age (ages 15-50) and people of Northern European descent. The clinical manifestations of AIP include acute and chronic symptoms that can be outlined into three phases: the prodromal phase, the visceral symptom phase, and the neurological phase. Major clinical symptoms involve severe abdominal pain, peripheral neuropathy, autonomic neuropathies, and psychiatric manifestations. Symptoms are often heterogeneous and vague, which can lead to life-threatening signs if not treated and managed appropriately. Whether treating AIP in its acute or chronic form, the cornerstone of treatment consists of the suppression of the production of ALA and PBG. The mainstay of managing acute attacks continues to comprise discontinuing porphyrogenic agents, adequate caloric support, heme treatment, and the treatment of symptoms. In recurrent attacks and chronic management, prevention is key with the consideration of liver transplantation and/or renal transplantation. In recent years, there has been great interest in emerging treatments that focus on a molecular level such as enzyme replacement therapy, ALAS1 gene inhibition, and even liver gene therapy (GT), which has changed the way of traditionally managing this disease and will pave the way for innovative therapies to come.
